Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 8;9(11):3599.
doi: 10.3390/jcm9113599.

Biotherapies in Uveitis

Mathilde Leclercq  1   2 , Anne-Claire Desbois  2   3   4 , Fanny Domont  2   3   4 , Georgina Maalouf  2   3   4 , Sara Touhami  5 , Patrice Cacoub  2   3   4 , Bahram Bodaghi  5 , David Saadoun  2   3   4
Affiliations
Review

Biotherapies in Uveitis

Mathilde Leclercq et al. J Clin Med. .

Abstract

Non-infectious uveitis (NIU) represents one of the leading causes of blindness in developed countries. The therapeutic strategy aims to rapidly control intra-ocular inflammation, prevent irremediable ocular damage, allow corticosteroid sparing and save the vision, and has evolved over the last few years. Anterior NIU is mostly managed with topical treatment in adults. However, for intermediate, posterior and pan-uveitis, notably when both eyes are involved, systemic treatment is usually warranted. Biotherapies are recommended in case of inefficacy or non-tolerance of conventional immunosuppressive drugs in non-anterior NIU. Anti-tumor necrosis factor alpha (anti-TNF-α) agents are by far the most widely used, especially adalimumab (ADA) and infliximab (IFX). In case of sight-threatening uveitis in Behçet's disease or in case of risk of severe recurrences, respectively IFX and ADA may be recommended as first-line therapy. Many questions are left unanswered; how long to treat NIU, how to discontinue anti-TNF-α agents, what biologic to use in case of anti-TNF-α failure? The objective of this review is to present an updated overview of knowledge on the use of biological treatments in NIU.

Keywords: Janus Associated Kinase (JAK) inhibitors; anti-TNF-α (anti-tumor necrosis factor alpha) agent; biotherapy; non-infectious uveitis; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol. 2005;140:509–516. - PMC - PubMed
    1. Touhami S., Diwo E., Sève P., Trad S., Bielefeld P., Sène D., Abad S., Brézin A., Quartier P., Paut I.K., et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin. Biol. Ther. 2019;19:477–490. doi: 10.1080/14712598.2019.1595578. - DOI - PubMed
    1. Bodaghi B., Cassoux N., Wechsler B., Hannouche D., Fardeau C., Papo T., Huong D.L.T., Piette J.-C., LeHoang P. Chronic Severe Uveitis. Medicine. 2001;80:263–270. doi: 10.1097/00005792-200107000-00005. - DOI - PubMed
    1. Sève P., Kodjikian L., Adélaïde L., Jamilloux Y. Uveitis in adults: What do rheumatologists need to know? Jt. Bone Spine. 2015;82:308–314. doi: 10.1016/j.jbspin.2015.06.002. - DOI - PubMed
    1. Thorne J.E., Suhler E., Skup M., Tari S., Macaulay D., Chao J., Ganguli A. Prevalence of Noninfectious Uveitis in the United States. JAMA Ophthalmol. 2016;134:1237–1245. doi: 10.1001/jamaophthalmol.2016.3229. - DOI - PubMed